vs
Kosmos Energy Ltd.（KOS）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
Kosmos Energy Ltd.的季度营收约是Pacira BioSciences, Inc.的1.7倍（$294.6M vs $177.4M），Pacira BioSciences, Inc.同比增速更快（5.0% vs -25.9%），过去两年Pacira BioSciences, Inc.的营收复合增速更高（-0.2% vs -16.5%）
科斯莫斯能源是一家美国上游石油企业，总部位于得克萨斯州达拉斯。公司目前在加纳、赤道几内亚近海以及墨西哥湾开展油气生产与开发业务，在毛里塔尼亚、塞内加尔近海拥有开发项目，还在纳米比亚、圣多美和普林西比、苏里南近海持有勘探许可。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
KOS vs PCRX — 直观对比
营收规模更大
KOS
是对方的1.7倍
$177.4M
营收增速更快
PCRX
高出30.9%
-25.9%
两年增速更快
PCRX
近两年复合增速
-16.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $294.6M | $177.4M |
| 净利润 | — | $2.9M |
| 毛利率 | — | — |
| 营业利润率 | -125.7% | 3.9% |
| 净利率 | — | 1.6% |
| 营收同比 | -25.9% | 5.0% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.80 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KOSPCRX
| Q1 26 | — | $177.4M | ||
| Q4 25 | $294.6M | $196.9M | ||
| Q3 25 | $311.0M | $179.5M | ||
| Q2 25 | $392.6M | $181.1M | ||
| Q1 25 | $290.1M | $168.9M | ||
| Q4 24 | $397.6M | $187.3M | ||
| Q3 24 | $407.8M | $168.6M | ||
| Q2 24 | $447.8M | $178.0M |
净利润KOSPCRX
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-124.3M | $5.4M | ||
| Q2 25 | $-87.7M | $-4.8M | ||
| Q1 25 | $-110.6M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $45.0M | $-143.5M | ||
| Q2 24 | $59.8M | $18.9M |
毛利率KOSPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
营业利润率KOSPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | -125.7% | 1.2% | ||
| Q3 25 | -34.2% | 3.5% | ||
| Q2 25 | -16.2% | 4.7% | ||
| Q1 25 | -32.4% | 1.2% | ||
| Q4 24 | -8.5% | 13.2% | ||
| Q3 24 | 26.1% | -82.8% | ||
| Q2 24 | 30.2% | 15.9% |
净利率KOSPCRX
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | -40.0% | 3.0% | ||
| Q2 25 | -22.3% | -2.7% | ||
| Q1 25 | -38.1% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 11.0% | -85.1% | ||
| Q2 24 | 13.3% | 10.6% |
每股收益（稀释后）KOSPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.80 | $0.05 | ||
| Q3 25 | $-0.26 | $0.12 | ||
| Q2 25 | $-0.18 | $-0.11 | ||
| Q1 25 | $-0.23 | $0.10 | ||
| Q4 24 | $0.00 | $0.38 | ||
| Q3 24 | $0.09 | $-3.11 | ||
| Q2 24 | $0.12 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $91.5M | $144.3M |
| 总债务越低越好 | $3.1B | — |
| 股东权益账面价值 | $528.6M | $653.9M |
| 总资产 | $4.7B | $1.2B |
| 负债/权益比越低杠杆越低 | 5.78× | — |
8季度趋势，按日历期对齐
现金及短期投资KOSPCRX
| Q1 26 | — | $144.3M | ||
| Q4 25 | $91.5M | $238.4M | ||
| Q3 25 | $64.0M | $246.3M | ||
| Q2 25 | $51.7M | $445.9M | ||
| Q1 25 | $49.8M | $493.6M | ||
| Q4 24 | $85.0M | $484.6M | ||
| Q3 24 | $51.6M | $453.8M | ||
| Q2 24 | $173.8M | $404.2M |
总债务KOSPCRX
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $372.2M | ||
| Q3 25 | $3.0B | $376.7M | ||
| Q2 25 | $2.9B | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $2.7B | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益KOSPCRX
| Q1 26 | — | $653.9M | ||
| Q4 25 | $528.6M | $693.1M | ||
| Q3 25 | $898.8M | $727.2M | ||
| Q2 25 | $1.0B | $757.8M | ||
| Q1 25 | $1.1B | $798.5M | ||
| Q4 24 | $1.2B | $778.3M | ||
| Q3 24 | $1.2B | $749.6M | ||
| Q2 24 | $1.1B | $879.3M |
总资产KOSPCRX
| Q1 26 | — | $1.2B | ||
| Q4 25 | $4.7B | $1.3B | ||
| Q3 25 | $5.1B | $1.3B | ||
| Q2 25 | $5.2B | $1.5B | ||
| Q1 25 | $5.3B | $1.6B | ||
| Q4 24 | $5.3B | $1.6B | ||
| Q3 24 | $5.5B | $1.5B | ||
| Q2 24 | $5.4B | $1.6B |
负债/权益比KOSPCRX
| Q1 26 | — | — | ||
| Q4 25 | 5.78× | 0.54× | ||
| Q3 25 | 3.31× | 0.52× | ||
| Q2 25 | 2.80× | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 2.29× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.3M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流KOSPCRX
| Q1 26 | — | — | ||
| Q4 25 | $35.3M | $43.7M | ||
| Q3 25 | $-27.6M | $60.8M | ||
| Q2 25 | $127.2M | $12.0M | ||
| Q1 25 | $-888.0K | $35.5M | ||
| Q4 24 | $175.7M | $33.1M | ||
| Q3 24 | $6.3M | $53.9M | ||
| Q2 24 | $223.7M | $53.2M |
自由现金流KOSPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
自由现金流率KOSPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
资本支出强度KOSPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
现金转化率KOSPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 3.74× | 2.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KOS
| Ghana Segment | $134.6M | 46% |
| Gulf Of America | $80.7M | 27% |
| Mauritania And Senegal | $54.9M | 19% |
| Equatorial Guinea Segment | $24.3M | 8% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
